

Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claims 1 to 17. (Cancelled)

18. (Withdrawn) A method for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

19. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies, and dementia pugilistica, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

20. (Withdrawn) The method according to claim 19, wherein the medical condition is Alzheimer's Disease.


21. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma, chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders,

hair loss, and pregnancy, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.


22. (Withdrawn) A method for the prevention and/or treatment of a medical condition selected from the group consisting of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment, cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia, and androgenetic alopecia, the method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9 to a patient in need thereof.

23. (Withdrawn) A process for the preparation of a compound of formula Ia according to claim 1, the process comprising a step selected from the group consisting of:


a) reacting a compound of formula B, wherein L^1 is a leaving group, with a compound of formula C, wherein P, R^1 , R^2 , R^3 , m, and n are as defined in claim 1, in a solvent at a temperature between +10°C and +150°C, to form the compound of formula Ia;




b) reacting a compound of formula XXV, wherein halo is halogen, with a compound of formula C, wherein R^1 , R^2 , R^4 , R^5 , and m are as defined in claim 1, in a solvent at a temperature between +10°C and +150°C, to form the compound of formula Ia;




c) reacting a compound of formula XXVII, wherein R^4 is C_{1-6} alkyl, with an amine of formula HNR^4R^5 , wherein R^1 , R^2 , and R^5 are defined in claim 1, and wherein R^4 in the amine and in the compound of formula XXVII is the same or different, in a solvent in the presence of a reagent at a reaction temperature between 0°C and reflux, to form the compound of formula Ia;



d) reacting a compound of formula XXVII with an amine of formula R^4R^5NH , wherein R^4 is C_{1-6} alkyl and R^1 , R^2 , R^5 , and m are defined in claim 1, and wherein R^4 in the amine and in the compound of formula XXVII is the same or different, neat or in a solvent, optionally in the presence of a base, at a temperature between -20°C and $+150^\circ\text{C}$, to form the compound of formula Ia; and




e) reducing the N-oxide in a compound of formula XXVIII with a reagent in a solvent at a temperature between 0°C and +100°C, to form the compound of formula Ia,




wherein R^1 , R^2 , R^4 , R^5 , and m are defined in claim 1.

24. (Withdrawn) A process for the preparation of a compound of formula Ib according to claim 1, the process comprising:
fluorinating a compound of formula Ia,



in a solvent in the presence of a fluorinating reagent and a base at a reaction temperature between -40 °C and +80 °C, to form the compound of formula Ib, wherein R¹, R², R³, m, and n are as defined in claim 1.

25. (Withdrawn) A compound according to formula XXV,



wherein:

Halo is halogen;

R³ is selected from the group consisting of halogen, nitro, C₁₋₆alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR⁴R⁵, C₀₋₆alkylcyano, C₀₋₆alkylCONR⁴R⁵, C₀₋₆alkyl(SO₂)NR⁴R⁵, C₀₋₆alkylNR⁴R⁵, and X¹R⁶;

X¹ is selected from the group consisting of a direct bond, O, CONR⁷R⁸, SO₂NR⁹R¹⁰, SO₂R¹¹, and NR¹²R¹³;

R⁷, R⁹, and R¹² are each independently selected from hydrogen and C₁₋₃alkyl;

R⁸, R¹⁰, R¹¹, and R¹³ are each independently selected C₀₋₄alkyl groups;

R⁶ is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms selected independently from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms selected independently from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and


R⁶ is linked to R⁸, R¹⁰, R¹¹, and R¹³.

26. (Withdrawn) The compound according to claim 25, wherein R³ is C₀₋₆alkylNR⁴R⁵; and n is 1.

27. (Withdrawn) A compound selected from the group consisting of:

1-[(6-Chloropyridin-3-yl)methyl]-4-methylpiperazine;
2-Chloro-5-(morpholin-4-ylmethyl)pyridine 1-oxide;
2-Chloro-5-(pyrrolidin-1-ylmethyl)pyridine 1-oxide;
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-methyl-1,4-diazepane;
2-Chloro-5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]pyridine 1-oxide;
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N,N-dimethylpyrrolidin-3-amine;
2-Chloro-5-[(4-methylpiperidin-1-yl)methyl]pyridine 1-oxide;
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-phenylpiperazine;
1-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine;
3-[[[(6-Chloro-1-oxidopyridin-3-yl)methyl](ethyl)amino]propanenitrile;
N-(4-Chlorobenzyl)-N-[(6-chloro-1-oxidopyridin-3-yl)methyl]-N-methylamine;
N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-(2-furylmethyl)-N-methylamine;
N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-methyl-N-phenylamine;
5-(Azetidin-1-ylmethyl)-2-chloropyridine 1-oxide;
2-Chloro-5-[(3-methylpiperidin-1-yl)methyl]pyridine 1-oxide;
N-[(6-Chloro-1-oxidopyridin-3-yl)methyl]-N-cyclohexyl-N-methylamine; and
2-Chloro-5-(piperidin-1-ylmethyl)pyridine 1-oxide.

28. (Withdrawn) A compound according to formula B,



wherein:

P is a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O, and S, of which at least one heteroatom is nitrogen;

L¹ is a leaving group;

R³ is selected from the group consisting of halogen, nitro, C₁₋₆alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR⁴R⁵, C₀₋₆alkylcyano, C₀₋₆alkylCONR⁴R⁵, C₀₋₆alkyl(SO₂)NR⁴R⁵, C₀₋₆alkylNR⁴R⁵, and X¹R⁶;

X¹ is selected from the group consisting of a direct bond, O, CONR⁷R⁸, SO₂NR⁹R¹⁰, SO₂R¹¹, and NR¹²R¹³;

R⁷, R⁹, and R¹² are each independently selected from hydrogen and C₁₋₃alkyl;

R⁸, R¹⁰, R¹¹, and R¹³ are each independently selected C₀₋₄alkyl groups;

R⁶ is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms independently selected from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and

R⁶ is linked to R⁸, R¹⁰, R¹¹, and R¹³.

29. (Withdrawn) The compound according to claim 28, wherein:

P is a pyridine or pyrimidine ring;

L¹ is a leaving group;


R^3 is selected from the group consisting of $C_{0-6}alkylCONR^4R^5$, $C_{0-6}alkyl(SO_2)NR^4R^5$, and $C_{0-6}alkylNR^4R^5$; and

n is 1.

30. (Withdrawn) A compound selected from the group consisting of:

2-Chloro-N-[2-(dimethylamino)ethyl]isonicotinamide;
1-(2-Chloroisonicotinoyl)-4-methylpiperazine;
6-Chloro-N-[2-(dimethylamino)ethyl]-N-methylnicotinamide;
4-{2-[(6-Chloropyrimidin-4-yl)oxy]ethyl}morpholine;
1-Benzyl-4-[(6-chloropyridine-3-yl)sulfonyl]piperazine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-(3-methylbutyl)piperazine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-isopropylpiperazine;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-ethylpiperazine;
1-[(5-Bromo-6-chloropyridin-3-yl)sulfonyl]-4-methylpiperazine;
6-Chloro-N-methyl-N-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
6-Chloro-N-[2-(dimethylamino)ethyl]pyridine-3-sulfonamide;
6-Chloro-N-[2-(dimethylamino)ethyl]-N-ethylpyridine-3-sulfonamide;
6-Chloro-N-[(1-ethylpyrrolidin-2-yl)methyl]pyridine-3-sulfonamide;
1-[(6-Chloropyridin-3-yl)sulfonyl]-4-methyl-1,4-diazepane; and
4-[(6-Chloropyridin-3-yl)sulfonyl]morpholine.

31. (Withdrawn) A compound according to formula C,



wherein:

R^1 is hydrogen;

R^2 is selected from the group consisting of halogen, nitro, C_{1-6} alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC_{1-6} alkyl NR^4R^5 , C_{0-6} alkylcyano, C_{0-6} alkyl $CONR^4R^5$, C_{0-6} alkyl $(SO_2)NR^4R^5$, C_{0-6} alkyl NR^4R^5 , and X^1R^6 ;

X^1 is selected from the group consisting of a direct bond, O, $CONR^7R^8$, $SO_2NR^9R^{10}$, SO_2R^{11} , and $NR^{12}R^{13}$;

R^7 , R^9 , and R^{12} are each independently selected from hydrogen and C_{1-3} alkyl;

R^8 , R^{10} , R^{11} , and R^{13} are each independently selected C_{0-4} alkyl groups;

R^6 is phenyl or a 5-, 6- or 7-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein:

the heterocyclic group is saturated or unsaturated,

the phenyl or 5-, 6- or 7-membered heterocyclic group is optionally fused with a 5- or 6-membered saturated or unsaturated ring containing atoms independently selected from C, N, O, and S, and

the phenyl or heterocyclic group is optionally substituted with one or two substituents selected from W; and

R^6 is linked to R^8 , R^{10} , R^{11} , and R^{13} .

32. (Withdrawn) The compound according to claim 31, wherein:

R^1 is hydrogen;

R^2 is selected from halogen and X^1R^6 ;

X^1 is a direct bond;

R^6 is a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S; and

m is 1 or 2.

33. (Withdrawn) A compound selected from the group consisting of:

5,6-Dibromo-1,3-dihydroindol-2-one;

5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one;

5-Thien-2-yl-1,3-dihydro-2H-indol-2-one;

5-(2-Furyl)-1,3-dihydro-2H-indol-2-one;
5-(1,3-Oxazol-5-yl)-1,3-dihydro-2H-indol-2-one;
5-(1,3-Thiazol-4-yl)-1,3-dihydro-2H-indol-2-one; and
5-(2-Methyl-1,3-thiazol-4-yl)-1,3-dihydro-2H-indol-2-one.

34 to 42. (Cancelled)

43. (Withdrawn) The process according to claim 23, wherein L^1 is a halogen.

44. (Withdrawn) The process according to claim 43, wherein the halogen is fluorine, chlorine, or bromine.

45. (Withdrawn) The process according to claim 23, wherein the halogen in process b) is fluorine, chlorine, or bromine.


46. (Withdrawn) The compound according to claim 28, wherein the leaving group is a halogen.

47. (Withdrawn) The compound according to claim 45, wherein the halogen is fluorine, chlorine, or bromine.

48. (Withdrawn) The compound according to claim 29, wherein the leaving group is a halogen.

49. (Withdrawn) The compound according to claim 47, wherein the halogen is chlorine.

50. (Currently amended) A compound of formula Ia [[or Ib]],



wherein the compound is in the form of a free base or a pharmaceutically acceptable salt thereof, and wherein:

P is a 6-membered ring containing one nitrogen;

R¹ is hydrogen;

R² is C₀₋₆alkylcyano;

R³ is ~~C₀₋₆alkyl~~ R⁴ R⁵ C₀₋₆alkylNR⁴R⁵;

m is 1;

n is 1;

R⁴ is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl, C₁₋₆alkylNR¹⁴R¹⁵, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

R⁵ is selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, C₀₋₆alkylheteroaryl, and C₁₋₆alkylNR¹⁴R¹⁵;

~~wherein~~ or R⁴ and R⁵ together with the N to which they are attached may together form a 6-membered heterocyclic group containing one nitrogen and one oxygen; and

wherein any C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, and C₀₋₆alkylheteroaryl group defined under R² to R⁵ is optionally substituted by one or more groups Z;

R¹⁴ and R¹⁵ are independently selected from hydrogen, C₁₋₆alkyl, and C₀₋₆alkylC₃₋₆cycloalkyl,

wherein R¹⁴ and R¹⁵ optionally together form a 5- or 6-membered heterocyclic group containing

one or more heteroatoms independently selected from N, O, and S, wherein the heterocyclic group is optionally substituted by a group Y;

Z is independently selected from the group consisting of oxo, halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, C₀₋₆alkylaryl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR¹⁶R¹⁷, NR¹⁶R¹⁷, CONR¹⁶R¹⁷, NR¹⁶(CO)R¹⁷, O(CO)C₁₋₆alkyl, (CO)OC₁₋₆alkyl, COR¹⁶, (SO₂)NR¹⁶R¹⁷, SO₂R¹⁶, SOR¹⁶, (CO)C₁₋₆alkylNR¹⁶R¹⁷, (SO₂)C₁₋₆alkylNR¹⁶R¹⁷, phenyl, heteroaryl, and a 5- or 6-membered heterocyclic group containing one or two heteroatoms independently selected from N, O, and S, wherein the phenyl, heteroaryl, and heterocyclic groups are optionally substituted by a group Y;

Y is selected from the group consisting of oxo, halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, C₀₋₆alkylaryl, C₀₋₆alkylC₃₋₆cycloalkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OC₁₋₆alkylNR¹⁶R¹⁷, NR¹⁶R¹⁷, CONR¹⁶R¹⁷, NR¹⁶(CO)R¹⁷, O(CO)C₁₋₆alkyl, (CO)OC₁₋₆alkyl, COR¹⁶, (SO₂)NR¹⁶R¹⁷, SO₂R¹⁶, SOR¹⁶, (CO)C₁₋₆alkylNR¹⁶R¹⁷, (SO₂)C₁₋₆alkylNR¹⁶R¹⁷, phenyl, C₀₋₆alkylaryl, and heteroaryl, wherein the phenyl, C₀₋₆alkylaryl, and heteroaryl groups are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, CN, OR¹⁶, C₁₋₆alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, and trifluoromethoxy;

R¹⁶ and R¹⁷ are independently selected from hydrogen and C₁₋₆alkyl, and wherein R¹⁶ and R¹⁷ optionally together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms independently selected from N, O, and S.

51. (New) A compound according to claim 50, wherein:

R⁵ is C₁₋₆alkylNR¹⁴R¹⁵, and

R⁴ is selected from hydrogen, C₁₋₆alkyl; or

R⁴ and R⁵ together with the N to which they are attached form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O, wherein said heterocyclic group may optionally be substituted by a group Y;

and wherein R¹⁴ and R¹⁵ may together form a 5-membered heterocyclic group containing one or more heteroatoms, selected independently from N, and O ;

Y is selected from C₁₋₆alkyl, C₀₋₆alkylaryl, NR¹⁶R¹⁷, phenyl, wherein the phenyl may be optionally substituted with nitro and trifluoromethyl;
wherein R¹⁶ and R¹⁷ may together form a 5-membered heterocyclic group containing one N heteroatom.

52. (New) A compound according to claim 50, wherein P is pyridyl; R² is CN; R³ is C₀₋₆alkylNR⁴R⁵; wherein R⁴ and R⁵ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

53. (New) A compound according to claim 52, wherein R⁴ and R⁵ together form a 6-membered heterocyclic group containing one or more heteroatoms selected independently from N and O.

54. (New) A compound selected from:

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-5-carbonitrile;

3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]methyl}pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methylpiperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

3-[5-(Azetidin-1-ylmethyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;

3-[5-(Morpholin-4-ylcarbonyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol, or

2-Hydroxy-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;

as a free base or a pharmaceutically acceptable salt thereof.

55. (New) A compound selected from:

2-Hydroxy-3-{4-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-[5-(pyrrolidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-methyl-1,4-diazepan-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

2-Hydroxy-3-{5-[(4-pyrrolidin-1-yl)piperidin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Chloro-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indol-2-ol;
6-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
5-Bromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-Fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-6-carbonitrile;
3-{5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-{5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;
3-{5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-2-hydroxy-1*H*-indole-5-carbonitrile;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-thien-2-yl-1*H*-indol-2-ol;
5-(2-Furyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol;
3-{3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-(trifluoromethyl)-1*H*-indol-2-ol;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-morpholin-4-ylethyl)nicotinamide;
6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-methyl-*N*-(1-methylpiperidin-4-yl)nicotinamide;
5-Nitro-3-{5-[(4-pyrrolidin-1-yl)piperidin-1-yl]carbonyl]pyridin-2-yl}-1*H*-indol-2-ol;
3-(5-{[3-(Dimethylamino)pyrrolidin-1-yl]carbonyl}pyridin-2-yl)-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(2-methyl-1,3-thiazol-4-yl)-1*H*-indol-2-ol;
3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-nitro-1*H*-indol-2-ol;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile;
2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile;
5,6-Dibromo-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indol-2-ol, or
2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile;
as a free base or a pharmaceutically acceptable salt thereof.

56. (New) A hydrochloride salt of a compound according to claim 55.

57. (New) 6-(2-Hydroxy-5-nitro-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide;
6-(5-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide;
2-Hydroxy-3-(5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl)-1*H*-indole-5-carbonitrile;
3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-thiazol-4-yl)-1*H*-indol-2-ol, or
3-{5-[(4-Methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-5-nitro-1*H*-indol-2-ol;
as a free base or a pharmaceutically acceptable salt thereof.

58. (New) A fumarate salt of a compound according to claim 57.

59. (New) A compound that is 2-Hydroxy-3-{5-[(4-phenylpiperazin-1-yl)methyl]pyridin-2-yl}-
1*H*-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof.

60. (New) A compound that is 2-Hydroxy-3-[5-({4-[2-nitro-4-(trifluoromethyl)phenyl]piperazin-
1-yl}methyl)pyridin-2-yl]-1*H*-indole-5-carbonitrile as a free base or a pharmaceutically
acceptable salt thereof.

61. (New) A compound that is 2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-
5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof.

62. (New) A compound that is 3-[5-(Morpholin-4-ylmethyl)pyridin-2-yl]-5-pyridin-3-yl-1*H*-
indol-2-ol as a free base or a pharmaceutically acceptable salt thereof.

63. (New) A compound that is 3-{5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-5-(1,3-
oxazol-5-yl)-1*H*-indol-2-ol as a free base or a pharmaceutically acceptable salt thereof.

64. (New) A pharmaceutical formulation comprising as active ingredient a therapeutically
effective amount of a compound according to any one of claims 54-63 in association with at least
one pharmaceutically acceptable carrier or diluent.